Related Experiment Video

Updated: Jun 18, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

beta-Adrenergic receptor blockers and heart failure risk after myocardial infarction: a critical review

Robert H Neumayr1, Paul J Hauptman

  • 1Division of Cardiology, FDT-15, Saint Louis University Hospital, 3635 Vista Avenue, Saint Louis, MO 63110, USA.

Current Heart Failure Reports
|December 2, 2009
PubMed

Insights

Beta-adrenergic receptor blockers are crucial for managing post-myocardial infarction remodeling and preventing heart failure. Early and long-term use improves outcomes, though optimal dosing and adherence remain key considerations.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Cardiac Remodeling

Background:

  • Myocardial infarction triggers complex cardiac remodeling, leading to left ventricular dilation and heart failure.
  • Autonomic imbalance, particularly sympathetic activation, significantly influences post-infarction remodeling.
  • Beta-adrenergic receptor blockers (beta-blockers) are a cornerstone therapy in managing patients post-myocardial infarction.

Discussion:

  • This review synthesizes clinical evidence supporting the early and sustained administration of beta-blockers.
  • The article addresses uncertainties regarding optimal beta-blocker dosage and treatment duration.
  • It highlights current guideline recommendations and discusses the underuse of beta-blocker therapy in clinical practice.

Key Insights:

  • Early initiation of beta-blocker therapy post-myocardial infarction is critical for mitigating adverse remodeling.
  • Long-term beta-blocker use demonstrates sustained benefits in preventing heart failure progression.
  • Addressing barriers to beta-blocker prescription and adherence is essential for improving patient outcomes.

Outlook:

  • Further research may clarify optimal beta-blocker selection and titration strategies.
  • Improved patient education and physician adherence to guidelines can enhance beta-blocker utilization.
  • Personalized approaches to beta-blocker therapy may optimize treatment for diverse patient populations.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...